---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-022506"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:29:20.096108+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes

## Summary
- Telomir-1 inhibited JMJD3, FBXL10, and FBXL11 histone demethylase enzymes in a Eurofins Discovery study.
- Overactivation of these enzymes silences tumor suppressors and activates pro-inflammatory and metabolic genes.
- Telomir-1 may restore normal gene expression, supporting development in cancer, autoimmune, neurodegeneration, and metabolic disorders.
- Data builds on prior results showing Telomir-1 reversed epigenetic silencing of STAT1 and TMS1 in PC3 prostate cancer xenograft models.
- Company is preparing to advance Telomir-1 into IND-enabling studies.

## SEC filing metadata
- accession: 0001641172-25-022506
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000164117225022506/0001641172-25-022506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000164117225022506/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-022506
- JSON: https://secwatch.observer/filing/0001641172-25-022506.json
- Plain text: https://secwatch.observer/filing/0001641172-25-022506.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.